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A B S T R A C T
Human papillomavirus (HPV) infection has been identified as major risk factor for cervical intraepithelial neoplasia
(CIN) and invasive cervical cancer. About 40 HPV viral types are commonly found in the genital tract. Most HPV infec-
tions resolve spontaneously, while persistent infection with oncogenic types, namely HPV 16 and 18 is necessary for CIN
to occur and progress to cancer. Cervical screening is presently based on the Pap smear that is designed to diagnose pre-
cancerous lesions and cervical cancer. The aim of this study was to investigate the prevalence of HPV DNA and to deter-
mine HPV types distribution among 361 women attending regular gynecological visit. There were 205 women (29±8
years old) without determined abnormal cervical lesions and 156 women (34±15 years old) with abnormal Pap smear;
low grade squamous intraepitehelial lesions (LSIL, n=69), high grade squamous intraepithelial lesions (HSIL, n=72)
and atypical squamous cells of undetermined significance (ASCUS, n=15). HPV DNA detection and genotyping was
performed by Hybrid Capture 2 assay and additionally by consensus and type-specific primers directed PCR. The overall
prevalence of high-risk HPV (hrHPV) in women with abnormal Pap smears was 67.9% (106/156), of which in ASCUS
33.4% (5/15), LSIL 62.3% (43/69) and HSIL 80.6% (58/72). In HPV positive specimens, HPV 16 was found as predomi-
nant type in 60.4% cases, followed by HPV 31 (8.5%), HPV 33 (6.6%) and HPV 18 (3.7%). In the group of women without
obvious cervical changes the overall hrHPV prevalence was 35.6% with HPV 16 found in 43.8% cases, followed by HPV
31 (17.8%), HPV 33 (9.5%) and HPV 18 (6.8%). In both study groups, women with and without cervical lesions, the prev-
alence of HPV of indeterminate type was 14.2% and 13.7%, respectively. Our results indicate that cervical intraepithelial
lesions are largely associated with HPV type 16, followed by HPV types 31, 33, 18 and HPV of indeterminate type. Al-
though there is a significant difference in hrHPV DNA prevalence among two groups, no significant differences between
particular hrHPV types distribution were observed.
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Introduction
Human papillomavirus (HPV) infection has been iden-
tified as major risk factor for cervical intraepithelial neo-
plasia (CIN) and invasive cervical cancer1,2,. Epidemio-
logical studies indicate a strong association of high-risk
human papillomavirus (hrHPV) genotypes with cervical
carcinoma and malignant transformation of cervical epi-
thelial cells1,2,3.
There are about 40 HPV viral types that are com-
monly found in the genital tract4. The most prevalent
hrHPV genotypes worldwide, which infect uterine cer-
vix, are HPV 16 (~53%), followed by HPV 18 (~15%),
HPV 45 (~9%), HPV 31 (~6%) and HPV 33 (~3%)1. Most
HPV infections resolve spontaneously over 6 to 18
months, while viral persistence is necessary for CIN le-
sions to progress5. According to the Croatian National
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Cancer Registry6, the incidence of cervical cancer in 2004
was 14.4 new cases per 100,000 women. There are only a
few reports describing HPV genotype distribution in ab-
normal cervical Pap smears in Croatia7,8. Initial screen-
ing is presently based on the Pap smear and cytological
examination. Cytology-based cervical cancer screening
using Pap smears and new technologies such as liq-
uid-based cytology have made significant impact on re-
ducing cervical cancer rates worldwide10. Early detection
and appropriate treatment of cervical lesions provide the
best approach to prevent cervical cancer11–13. Treatment
of pre-invasive lesions identified in screening program-
mes is very effective, but care should be taken to avoid
unnecessary over-treatment. HPV testing and prophy-
lactic vaccination will change substantially the use of
cervical cytology, probably in favour to HPV testing as
the primary test in secondary prevention10.
Current studies evaluate the implementation of HPV
testing in screening algorithms for the women with an
increased risk for development of cervical cancer and
those which could undergo unnecessary re-testing14,15.
The aim of this study was to investigate the preva-
lence of HPV DNA and HPV types distribution among
361 women attending regular gynecological visit. Accord-
ing to cytological findings they were separated in the two
study groups: women with normal and women with ab-
normal Pap smears.
Materials and Methods
This study was performed among 361 women attend-
ing regular gynecological examination in Zagreb and
Rijeka County between 2004 and 2006. Informed consent
was sign by all women who participated in the study. Cer-
vical lesions were classified according to »Zagreb 2002«
Uniform Classification of Uterine Cervix Cytological Find-
ings in Croatia9 adapted from the Bethesda system into
normal epithelium, low-grade intraepithelial lesions (LSIL
or CIN1) indicating a low risk of malignant transforma-
tion which may resolve spontaneously, high-grade in-
traepithelial lesions (HSIL, CIN2 or CIN3-carcinoma in
situ) having a potential to progress to invasive cervical
cancer, and finally borderline Pap smears, classified as
atypical squamous cells of undetermined significance
(ASCUS). Cervical smears were obtained from 156 wo-
men (34±15 years old) with LSIL (n=69) and HSIL
(n=72) and ASCUS (n=15). All women from this group
were diagnosed by cytological examination followed by
subsequent HPV detection and genotyping. A second
group of women consisted of 205 women (29±8 years old)
undergoing regular preventive gynecological examina-
tions. Women in this group had normal cytological smears
and were also tested for the presence of HPV DNA, fol-
lowed by subsequent genotyping of HPV DNA positive
cases. All cervical smears were taken with cervical brush
and collected to specimen transport medium (Digene Di-
agnostic, USA) and stored at +4 °C until testing. Samples
were divided into aliquots for hybridization in the liquid
phase and polymerase chain reaction (PCR) tests.
Hybrid capture HPV assay
The Hybrid Capture assay (HC2, Digene Diagnostic,
USA) is based on signal amplification by chemilumines-
cent detection16. Specimens containing the target DNA
hybridize with a specific HPV RNA probe cocktail. The
RNA:DNA hybrids are captured onto the surface of a tube
coated with antibodies specific for hybrids and detected
with a chemiluminescent substrate. The intensity of the
light emitted denotes the amount of target DNA in the
specimen. RNA probe mix for the detection of hrHPV
types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
was used according to the manufacturer’s instructions.
DNA extraction and PCR analysis
DNA was isolated by NucleoSpinTissue kit (Ma-
charey-Nagel, Duren, Germany) according to the manu-
facturer’s instructions. Successful DNA extraction was
confirmed by the presence of b-globin gene sequence17.
Detection of HPV DNA was performed by PCR using E6
and E7 consensus primers pU-1M/pU-2R, which are spe-
cific for HPV 16, 18, 31, 33, 35, 52 and 58 types18 (Human
Papillomavirus Typing Set, Takara Biomedicals, Japan).
HPV typing of HPV 16, 18 and 33 was performed by PCR
with primers chosen within the E6 region (Human Papil-
lomavirus Detection Set, Takara Biomedicals, Japan)19,
while HPV 31 was amplified with primers chosen within
the E7 region of the HPV genome3.
PCR products of 228 to 268 bp for generic amplifica-
tion, and 100 and 140 bp for type-specific amplification
were resolved by electrophoresis on 1.5 to 2% agarose gel.
Statistical analysis
HPV prevalence was expressed as percentage of HPV
positives against all cases tested for HPV. The prevalence
of individual hrHPV genotypes was determined as single
infection. Multiple hrHPV infections were defined as two
hrHPV genotypes. The distribution of non-continuous
cytological variables versus HPV status was analysed
with the Chi-square test (c2). P values of <0.05 were
used as the cut-off for statistical significance.
Results and Discussion
High-risk HPV DNA was detected in 179 and 154 out
of 361 cervical smears by HC2 and PCR, respectively (Ta-
ble 1). It was demonstrated that correlation between
HC2 and PCR was between 85.8% (91/106) to 86.3%
(63/73) This data were additionally confirmed by type-
-specific PCR amplification which failed to detect any
HPV type in 13.7% and 14.2% of cases in the group with
CIN and the group with normal cervical findings, respec-
tively, and was referred as HPV of indeterminate types
(Table 1).
In 25 women, the positive HPV-DNA results obtained
by HC2 test were not confirmed by type-specific PCR am-
plification for HPV types 16, 18, 31 and 33, suggesting a
presence of another HPV type which could be detected by
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the probes of broader HPV type spectrum in the HC2
assay16.
Comparison of the HC2 and PCR with hrHPV prim-
ers demonstrated concordant results in as many as
86.0% (154/179) of HPV-DNA positive samples. There-
fore, PCR method with E7 consensus primers pU-1M/
pU-2R which achieved sensitivity comparable to HC2 is
also a good method for screening assessments. Develop-
ment of methods for simple, rapid and accurate detection
of HPV DNA has a central role in many strategies de-
signed to reduce the risk of cervical cancer20,21.
High-risk HPV infection was present in 73 out of 205
(35.6%) women with normal Pap smear (control group)
and in 106 out of 156 (67.9%) women with abnormal Pap
smear. The hrHPV prevalence is significantly different
between these two groups (c2=37.060, p£0.001) (Table
1). Statistically significant difference in hrHPV preva-
lence was detected in women with LSIL – 62.3% (43/69)
and those with HSIL – 80.6% (58/72) compared to women
with ASCUS – 33.3% (5/15) (c2=14.511, p£0.001 for
trend).
Out of all HPV positive specimens HPV 16 was the
predominant type in all cytological entities detectable in
60.0% of ASCUS, 55.8% of LSIL and 63.8% of HSIL as
well as in 43.8% women with normal Pap smears (Table
1). In most studies HPV 16 was found to be the most
prevalent HPV genotype in cervical cancer, precursors le-
sions and cytologically normal Pap smears5,22. The asso-
ciation of HPV types and histological type of the cancer is
well established; HPV16 being the most frequently found
genotype in squamous cell carcinoma (SCC), while HPV18
in adenocarcinoma23. Our previous study demonstrated
the high overall prevalence of HPV-DNA in cervical neo-
plasia (>90%)24. In CIN3 and SCC, HPV 16 was the most
common hrHPV type, identified in 65% and 52% of cases,
respectively24. Grce et al. have demonstrated that among
Croatian non-pregnant women increase in hrHPV preva-
lence is associated with CIN grade changes from 1 to 3
(35.1%, 64.6% and 81.0%, respectively) with HPV 16 be-
ing predominant type in all cervical lesions7.
HPV 18 was detected in 3.7% (4/106) of women with
intraepithelial lesions and in 6.8% (5/73) specimens of
women with normal smears. HPV 31 and 33 are detected
in 8.5% (9/106) and 6.6% (7/106) cases of CIN, respec-
tively, and in 17.8% (13/73) and 9.5% (7/73) of normal
smears. The high prevalence of HPV 31 (17.8%) was
found in women with normal Pap smears, although the
most relevant studies report average prevalence between
5 and 8%1,3,7,8. Had`isejdi} et al.24 have demonstrated the
unexpected high prevalence of HPV 31 of 10% and 26%
in CIN3 and SCC, but in almost half of these cases as
part of multiple infection.
HPV of indeterminate type was found in 14.2% (15/106)
and 13.7% (10/73) of cases from abnormal and normal
Pap smear groups, respectively. In LSIL cytological group,
the prevalence of indeterminate HPV type 20.9% was the
highest one, although with no statistical significance.
The possible explanation for this finding could be the fact
that HPV of indeterminate type could be low- as well as
high-risk HPV types; there is always a possibility of
cross-hybridization of HC2 RNA probes and in case of
PCR with generic primers amplification of a large num-
ber of different HPV types.
Low prevalence of multiple infections in LSIL and
HSIL as well as in normal Pap smears was found in 6.9%,
5.2% and 8.2% cases, respectively. These data suggest
that single hrHPV infection in LSIL and HSIL (>90%)
are significant for establishing and maintaining prolife-
rative growth of epithelial cells25.
Conclusion
Our results indicate that cervical intraepithelial le-
sions are largely associated with HPV types 16, 31 and 33
followed by HPV 18 and HPV of indeterminate type. A
significant difference between hrHPV prevalence among
the group of women attending regular examination with
normal cytology and the group of women with abnormal
Pap smear was observed. However, no significant differ-
ences between particular hrHPV types distribution were
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n % n % n % n % n % n % n % n %
ASCUS 15 10 66.7 5 33.3 3 60.0 0 - 1 20.0 0 - 0 - 1 20.0
LSIL 69 26 37.7 43 62.3 24 55.8 1 2.3 3 6.9 3 6.9 9 20.9 3 6.9
HSIL 72 14 19.4 58 80.6 37 63.8 3 5.2 5 8.6 4 6.9 6 10.3 3 5.2
Women with abnormal
Pap smears (34±15 years)
156 50 32.1 106 67.9 64 60.4 4 3.7 9 8.5 7 6.6 15 14.2 7 6.6
Women with normal
Pap smears (29±8 years)
205 132 64.4 73 35.6 32 43.8 5 6.8 13 17.8 7 9.5 10 13.7 6 8.2
hrHPV – high-risk human papillomavirus, *HPV indeterminate: HPV types other than 16, 18, 31, 33, **Multiple HPV infections: posi-
tive for HPV 16/18, 16/31 and 18/31
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observed between the two groups of women. The signifi-
cance of higher prevalence of HPV 31 type in women
with normal Pap smears as well as indeterminate HPV
type in low-grade intraepithelial lesions should be con-
sidered in future epidemiological studies of hrHPV prev-
alence in borderline cervical intraepithelial lesions.
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PREVALENCIJA HPV U CERVIKALNIM BRISEVIMA UZETIM PRIGODOM REDOVITOG
GINEKOLO[KOG PREGLEDA
S A @ E T A K
Infekcija humanim papilomavirusom (HPV) je jedan od glavnih rizi~nih ~imbenika za nastanak cervikalne intra-
epitelijske neoplazije (CIN) i invazivnog karcinoma vrata maternice. Oko 40 HPV tipova je utvr|eno u urogenitalnoj
regiji `ena. Iako u ve}ini slu~ajeva infekcija prolazi spontano, trajna infekcija s HPV tipovima visokog rizika, posebice
HPV-16 i HPV-18 je neophodna za nastanak CIN-a i invazivnog karcinoma. Probiranje na prekancerozne lezije i kar-
cinom vrata maternice danas se temelji na citolo{kom pregledu Papa-razmaza. Cilj i svrha ove studije je bila da se ispita
prevalencija HPV-DNK i odredi raspodjela HPV tipova visokog rizika u skupini `ena (n=361), koje su do{le na redovni
ginekolo{ki pregled i pristale da sudjeluju u studiji. U skupini je bilo 205 `ena `ivotne dobi 29±8 godina s urednim
Papa-nalazom i 156 `ena u dobi 34±8 godina s promjenama u Papa-nalazu; s niskim stupnjem intraepitelijske lezije
(LSIL, engl. Low grade Squamous Intraepithelial Lesions) 68 `ena, s visokim stupnjem intraepitelijske lezije (HSIL,
engl. High grade Squamous Intraepithelial Lesions) 72 `ene i s atipi~nim nalazom plo~astih stanica neodre|enog zna-
~aja (ASCUS, engl. Atypical Squamous Cells of Undetermined Significance) 15 `ena. Odre|ivanje HPV-DNK i tipizacija
provedeni su metodama Hybrid Capture 2 (HC2) i lan~anom reakcijom polimeraze (PCR, engl. Polymerose Chain Reac-
tion) temeljenim na koncenzus i tip-specifi~nim po~etnim oligonukleotidima. Ukupna prevalencija HPV-DNA visokog
rizika u `ena s abnormalnim Papa-razmazom bila je 67,9% (106/156) i to s ASCUS-om 33,4% (5/15), LSIL-om 62,3%
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(43/69) i HSIL-om 80,6% (58/72). Od svih HPV-pozitivnih uzoraka u toj skupini, HPV-16 ja na|en u 60,4% `ena, HPV-
-31 u 8,5%, HPV-33 u 6,6% i HPV-18 u 3,7% `ena. U skupini `ena bez promjena na vratu maternice, ukupna pre-
valencija HPV-DNK visokog rizika je utvr|ena u 35,6% `ena, s udjelom HPV-16 od 43,8%, HPV-31 s 17,8%, HPV-33 s
9,5% i HPV-18 s 6,8%. U obje skupine, prevalencija neodre|enog HPV-tipa bila je 14,2% i 13,7%. Na{i rezultati su
pokazali da su intraepitelijska o{te}enja vrata maternice udru`ene s HPV-tipovima visokog rizika i to 16, 31, 33 i 18 u
vi{e od 85% slu~ajeva, dok preostali dio predstavljaju netipizirani HPV-tipovi.
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